28 Aprilie 2009
Ranbaxy Romania: 8.4% decline in sales
Ranbaxy Romania, subsidiary of India’s largest pharmaceutical firm reported a de-growth of 8.4% in first quarter, down to 945 million Rupees (19 million dollars) following the steep devaluation of the local currency and uncertainty regarding the new regulations introduced by the Ministry of Public Health.
The company continues to lead the generics and OTC segment, with No1 ranking and No7 in total market, according to own statements.
Ranbaxy group reported net sales of 1.6 Rupees (313 bln dollars) for the quarter ended March 31, down 4% from prior-year period.
For 2009, the company expects to achieve sales of approximately 70 billion Rupees (1.4 billion dollars).
Ranbaxy Laboratories, India’s largest drugmaker, bought in March 2006 96.7% stake in Terapia Cluj-Napoca from Advent International, paying 324 million dollars, in a bid to expand operations in European market.
Ranbaxy group reported net sales of 1.6 Rupees (313 bln dollars) for the quarter ended March 31, down 4% from prior-year period.
For 2009, the company expects to achieve sales of approximately 70 billion Rupees (1.4 billion dollars).
Ranbaxy Laboratories, India’s largest drugmaker, bought in March 2006 96.7% stake in Terapia Cluj-Napoca from Advent International, paying 324 million dollars, in a bid to expand operations in European market.